NO174833C - Fremgangsmåte for fremstilling av et injiserbart preparat - Google Patents

Fremgangsmåte for fremstilling av et injiserbart preparat

Info

Publication number: NO174833C
Authority: NO; Norway
Prior art keywords: vesicles; preparation; fungal infections; systemic fungal; particles
Prior art date: 1986-08-21

Application number

NO873492A

Other languages

English (en)

Other versions

NO873492L (no

NO873492D0 (no

NO174833B (no

Inventor

Jill Adler-Moore

Ronald Carl Gamble

Richard Thomas Proffitt

Original Assignee

Vestar Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-08-19

Publication date

1994-07-20

1987-08-19 Application filed by Vestar Inc filed Critical Vestar Inc

1987-08-19 Publication of NO873492D0 publication Critical patent/NO873492D0/no

1988-02-22 Publication of NO873492L publication Critical patent/NO873492L/no

1994-04-11 Publication of NO174833B publication Critical patent/NO174833B/no

1994-07-20 Publication of NO174833C publication Critical patent/NO174833C/no

Links

238000000034 method Methods 0.000 title abstract 2
230000000843 anti-fungal effect Effects 0.000 abstract 3
229940121375 antifungal agent Drugs 0.000 abstract 3
206010017533 Fungal infection Diseases 0.000 abstract 2
208000031888 Mycoses Diseases 0.000 abstract 2
230000003115 biocidal effect Effects 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Medical Informatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO873492A 1986-08-21 1987-08-19 Fremgangsmåte for fremstilling av et injiserbart preparat NO174833C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89906486A	1986-08-21	1986-08-21

Publications (4)

Publication Number	Publication Date
NO873492D0 NO873492D0 (no)	1987-08-19
NO873492L NO873492L (no)	1988-02-22
NO174833B NO174833B (no)	1994-04-11
NO174833C true NO174833C (no)	1994-07-20

Family

ID=25410437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873492A NO174833C (no)	1986-08-21	1987-08-19	Fremgangsmåte for fremstilling av et injiserbart preparat

Country Status (14)

Country	Link
US (1)	US5874104A (no)
EP (1)	EP0260811B1 (no)
JP (1)	JPH0615475B2 (no)
KR (1)	KR950013747B1 (no)
AT (1)	ATE66597T1 (no)
AU (1)	AU606880B2 (no)
CA (1)	CA1292184C (no)
DE (1)	DE3772498D1 (no)
DK (1)	DK168982B1 (no)
ES (1)	ES2051740T3 (no)
GR (1)	GR3002852T3 (no)
HK (1)	HK115393A (no)
IE (1)	IE60901B1 (no)
NO (1)	NO174833C (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2620028B2 (fr) *	1986-12-05	1994-02-25	Ire Celltarg Sa	Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
US4999199A (en) *	1988-11-10	1991-03-12	Board Of Regents, The University Of Texas System	Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
EP0598116B1 (en) *	1989-11-27	1996-07-24	Nippon Shinyaku Company, Limited	Fat emulsion
JPH06509058A (ja) *	1991-01-14	1994-10-13	ボード、オブ、リージェンツ、ザ、ユニバーシティー、オブ、テキサス、システム	リポソームニスタチン及びアンホテリシンｂの抗ｈｉｖ活性
CA2120917A1 (en) *	1991-10-25	1993-04-29	Kazumi Ogata	External preparation for treating hemorrhoidal diseases
JP2915296B2 (ja) *	1993-08-30	1999-07-05	宇野潤	抗真菌製剤
GB9519654D0 (en) *	1995-09-27	1995-11-29	Nycomed Imaging As	Stabilised phospholipid compositions
SK101398A3 (en)	1996-01-25	1998-12-02	Schering Ag	Improved concentrated injection and infusion solutions for intravenous administration
GB9721901D0 (en) *	1997-10-16	1997-12-17	Univ Manchester	Particles
IL136342A0 (en) *	1997-12-01	2001-05-20	Yissum Res Dev Co	Formulation for topical treatment of skin infections
IT1301807B1 (it) *	1998-06-25	2000-07-07	Tiberio Bruzzese	Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US6413537B1 (en)	2000-03-10	2002-07-02	Wisconsin Alumni Research Foundation	Nystatin formulation having reduced toxicity
JP4786041B2 (ja) *	2001-03-02	2011-10-05	丸善製薬株式会社	渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) *	2002-11-15	2010-01-26	Albert Einstein College Of Medicine Of Yeshiva University	Methods of applying ionization radiation for therapy of infections
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007038619A2 (en) *	2005-09-27	2007-04-05	Amunix, Inc.	Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
BRPI0618643A2 (pt)	2005-11-09	2011-09-06	Combinatorx Inc	composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
CA2841386A1 (en)	2005-12-30	2007-07-12	Zensun (Shanghai) Science & Technology Limited	Extended release of neuregulin for improved cardiac function
CA2695374A1 (en) *	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
EP2564857B1 (en)	2008-03-06	2017-05-03	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-inflammatory agents
ES2610356T3 (es)	2009-02-03	2017-04-27	Amunix Operating Inc.	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
MX354555B (es)	2009-06-08	2018-03-09	Amunix Operating Inc	Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
PT2440228T (pt)	2009-06-08	2018-12-24	Amunix Operating Inc	Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
JP6205133B2 (ja)	2009-07-10	2017-09-27	プレジデントアンドフェローズオブハーバードカレッジ	抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
EP3222287A1 (en)	2009-08-24	2017-09-27	Amunix Operating Inc.	Coagulation factor ix compositions and methods of making and using same
CA2735344C (en) *	2009-10-16	2020-04-14	Lifecare Innovations Pvt. Ltd.	Formulation for treating fungal infection
EP2774935B8 (en)	2009-10-30	2017-06-21	NTF Therapeutics, Inc.	Improved neurturin molecules
AU2010330747B2 (en)	2009-12-18	2016-08-11	Achelios Therapeutics, Inc.	Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8716478B2 (en)	2010-01-27	2014-05-06	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
US9757462B2 (en)	2010-11-19	2017-09-12	Sapporo Medical University	Combined pharmaceutical preparation
ES2771208T3 (es)	2012-02-15	2020-07-06	Bioverativ Therapeutics Inc	Composiciones de factor VIII y métodos de preparación y uso de las mismas
DK2822577T3 (en)	2012-02-15	2019-04-01	Bioverativ Therapeutics Inc	RECOMBINANT FACTOR VIII PROTEINS
NZ630848A (en)	2012-06-08	2016-07-29	Alkermes Inc	Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP3033097B1 (en)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Factor viii-xten fusions and uses thereof
EP3122380B1 (en)	2014-03-25	2025-03-19	The Government of the United States of America as represented by the Secretary of the Army	Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
JP2017536421A (ja)	2014-12-01	2017-12-07	アケリオスセラピューティクス，インコーポレーテッド	片頭痛及び疼痛に関連する状態を処置するための方法及び組成物
TWI741992B (zh)	2015-08-03	2021-10-11	美商百歐維拉提夫治療公司	因子ｉｘ融合蛋白以及其製備及使用方法
WO2017024037A1 (en)	2015-08-03	2017-02-09	President And Fellows Of Harvard College	Charged ion channel blockers and methods for use
CN112812143A (zh)	2015-11-06	2021-05-18	佐剂技术公司	三萜皂苷类似物
CN110023321A (zh)	2016-08-17	2019-07-16	索尔斯蒂斯生物有限公司	多核苷酸构建体
MX2019006444A (es)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
EP3697802A4 (en)	2017-10-16	2021-11-24	Adjuvance Technologies, Inc.	TRITERPENIC SAPONIN ANALOGUES
MA52630B1 (fr)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc.	Procédés de traitement de l'hémophilie a
US10927096B2 (en)	2019-03-11	2021-02-23	Nocion Therapeutics, Inc.	Ester substituted ion channel blockers and methods for use
US10786485B1 (en)	2019-03-11	2020-09-29	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CN113811305A (zh)	2019-03-11	2021-12-17	诺西恩医疗公司	带电的离子通道阻滞剂及其使用方法
SG11202109720WA (en)	2019-03-11	2021-10-28	Nocion Therapeutics Inc	Charged ion channel blockers and methods for use
US10780083B1 (en)	2019-03-11	2020-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US20220401391A1 (en)	2019-05-09	2022-12-22	Apkarian Tech Llc	Methods and compositions for treating pain
US20220307013A1 (en)	2019-08-30	2022-09-29	The Regents Of The University Of California	Gene fragment overexpression screening methodologies, and uses thereof
BR112022008575A2 (pt)	2019-11-06	2022-08-09	Nocion Therapeutics Inc	Bloqueadores de canal iônico carregado e métodos para uso
CA3155568A1 (en)	2019-11-06	2021-05-14	Bridget Mccarthy Cole	Charged ion channel blockers and methods for use
WO2021183639A1 (en)	2020-03-11	2021-09-16	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US12162851B2 (en)	2020-03-11	2024-12-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
KR20230041711A (ko)	2020-06-25	2023-03-24	아뮤닉스 파마슈티컬스, 인크.	Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
EP4314073A4 (en)	2021-03-24	2025-02-19	Alkermes, Inc.	Upar antibodies and fusion proteins with the same
WO2023175454A1 (en)	2022-03-14	2023-09-21	Pfizer Inc.	Methods for producing an adjuvant
CA3250825A1 (en)	2022-03-21	2023-09-28	The Board Of Trustees Of The University Of Illinois	PROSTHETIC COMPOSITIONS WITH ION CHANNELS COMPRISING AMPHOTEROTIN B LIPID-COATED CRYSTALS
EP4626405A1 (en)	2022-12-01	2025-10-08	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2025057058A1 (en)	2023-09-13	2025-03-20	Pfizer Inc.	Methods for producing an adjuvant
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310505A (en) *	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) *	1983-02-10	1985-02-05	Vestar Research Incorporated	Method for labeling phagocytic cells
GB2135647A (en) *	1983-02-15	1984-09-05	Squibb & Sons Inc	Method of preparing liposomes and products produced thereby
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
DK482685D0 (da) *	1984-10-22	1985-10-21	Hope Nat Medical Center	Fremgangsmaade til tilfoersel af micellulaere partikler, der indkapslerbilleddannende og kemoterapeutiske midler, til tumorer i et legeme
US4753788A (en) *	1985-01-31	1988-06-28	Vestar Research Inc.	Method for preparing small vesicles using microemulsification
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin

1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-14 EP EP87307221A patent/EP0260811B1/en not_active Expired - Lifetime
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active Expired - Lifetime
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/en not_active IP Right Cessation
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPS6366123A (ja)	1988-03-24
NO873492L (no)	1988-02-22
US5874104A (en)	1999-02-23
EP0260811B1 (en)	1991-08-28
KR880002531A (ko)	1988-05-09
DE3772498D1 (de)	1991-10-02
EP0260811A2 (en)	1988-03-23
KR950013747B1 (ko)	1995-11-15
NO873492D0 (no)	1987-08-19
EP0260811A3 (en)	1988-07-20
JPH0615475B2 (ja)	1994-03-02
DK434187D0 (da)	1987-08-20
ATE66597T1 (de)	1991-09-15
ES2051740T3 (es)	1994-07-01
NO174833B (no)	1994-04-11
IE60901B1 (en)	1994-08-24
DK434187A (da)	1988-02-22
GR3002852T3 (en)	1993-01-25
CA1292184C (en)	1991-11-19
DK168982B1 (da)	1994-07-25
IE872148L (en)	1988-02-21
AU606880B2 (en)	1991-02-21
AU7716087A (en)	1988-02-25
HK115393A (en)	1993-11-05

Publication	Publication Date	Title
NO174833C (no)	1994-07-20	Fremgangsmåte for fremstilling av et injiserbart preparat
AU587232B2 (en)	1989-08-10	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
US6221385B1 (en)	2001-04-24	Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
AU8141791A (en)	1991-11-07	Method for determining unentrapped ionizable bioactive agents in liposome preparations
NO901852L (no)	1990-08-01	Fremgangsmaate for fremstilling av liposomer.
NO180147C (no)	1997-02-26	Fremgangsmåte for fremstilling av HDLC eller et liposom innbefattende et polyen-antisopp-antibiotikum og et lipid
DK32388A (da)	1988-07-28	Phospholipid-baeremiddel for vand-uoploeselige aktive bestanddele
ATE86104T1 (de)	1993-03-15	Mehrstufen-einkapselungs/ladeverfahren zur herstellung von lipophile heilmittel enthaltenden liposomen.
Demel et al.	1966	Penetration of lipid monolayers by psychoactive drugs

Legal Events

Date	Code	Title	Description
2007-08-27	MK1K	Patent expired